ArticleTranslational stroke research2026
Exosomal Protein Biomarkers for Predicting Early Neurological Deterioration Following Intravenous Thrombolysis in Acute Ischemic Stroke.
Article in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Early neurological deterioration due to ischemic progression (ENDi) remains a poorly understood complication in acute ischemic stroke (AIS). We aim to uncover exosomal protein signatures for ENDi risk prediction and potential targets for intervention. From 110 prospectively enrolled AIS patients undergoing thrombolysis, we selected 3 ENDi and 5 age- and sex-matched early neurological improvement (ENI) patients. Plasma exosomes isolated before and 24 h post-thrombolysis were subjected to 4D-DIA proteomics, followed by Gene Set Enrichment Analysis (GSEA) and cellular origin analyses. Baseline differentially expressed proteins (DEPs) were further analyzed via functional enrichment and protein-protein interaction networks to identify candidate biomarkers and validated by ELISA in an independent cohort. We identified 1,238 exosomal proteins, among which 69 DEPs at baseline distinguished the ENDi from ENI patients. Cellular origin analysis revealed a post-thrombolytic reduction in monocyte-derived exosomal proteins in the ENDi group, while the ENI group showed upregulation of naive B cell-derived exosomal proteins. Regarding biological processes, ENDi after thrombolysis was characterized by activation of the coagulation and neuroinflammation pathways, along with suppression of the complement pathway and humoral immunity. From thrombo-inflammatory-related DEPs, we identified C-C motif chemokine 5 (CCL5) as a promising biomarker, and independent validation confirmed that elevated baseline plasma exosomal CCL5 was correlated with ENDi. In conclusion, our study highlights the role of exosomal proteins in immunothrombosis and establishes CCL5 as a potential predictor for ENDi. Importantly, we propose a novel mechanism involving immunoglobulin- and complement-related humoral immune suppression in the pathogenesis of ENDi, offering new directions for therapeutic intervention.
Indexed as
Identifiers
42081015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.